Safety Study of a Cell-based Cancer Vaccine in Melanoma (GeniusVac-Mel4)

This study is currently recruiting participants.
Verified July 2013 by University Hospital, Grenoble
Etablissement Français du Sang
Institut National de la Santé Et de la Recherche Médicale, France
Université Joseph Fourier
Information provided by (Responsible Party):
University Hospital, Grenoble Identifier:
First received: May 22, 2013
Last updated: July 2, 2013
Last verified: July 2013

The primary objective of this study will be to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a cell-based cancer vaccine, in patients with melanoma. The secondary objectives will be to determine immune response and clinical efficacy of such injections in patients with melanoma.

Condition Intervention Phase
Tumor Vaccines
Effects of Immunotherapy
Biological: GeniusVac-Mel4
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of GeniusVac-Mel4 in Patients With Melanoma

Resource links provided by NLM:

Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • Tolerability and safety of a multiple sub-cutaneous injections of GeniusVac-Mel4. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Safety and tolerance will be monitored by performing clinical laboratory tests, assessments of vital signs, full clinical examination, occurrence of adverse events.

Secondary Outcome Measures:
  • Evaluation of the immune response [ Time Frame: 1 year ] [ Designated as safety issue: No ]

    The induction of an immune response will be analyzed ex vivo by measuring:

    • The frequency of the T lymphocytes specific for each of the peptides used in the protocol.
    • The functionality of these T-cells (cytotoxicity and IFN-g secretion)

  • Evaluation of the clinical response [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The evolution of the disease will be determined with a clinical examination and scanner exams. The overall tumor response will be evaluated in accordance RECIST 1.1 and immune-related response criteria (irRC).

Estimated Enrollment: 9
Study Start Date: May 2013
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GeniusVac-Mel4
Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
Biological: GeniusVac-Mel4
Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma

Detailed Description:

GeniusVac-Mel4 corresponds to an irradiated allogeneic plasmacytoid dendritic cell line loaded with 4 melanoma peptides. This cell line is HLA-A*0201, a phenotype found in 40% of the European population. This approach exploits the pDC line high capacity of boosting anti-tumor cytotoxic response against melanoma antigens in HLA-A*201 melanoma patients. In the preclinical studies, its efficacy was shown in melanoma in vivo in humanized mice and ex vivo from the PBMC (peripheral blood mononuclear cells) of patients.

It is planned to include patients in three dose-escalating groups (4, 20, 60 millions of GeniusVac-Mel4 cells). 3 patients will be recruited in each dose group of the trial.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically confirmed metastatic melanoma (at stage IIIC or stage IV under the AJCC 2009 classification not surgically resectable.
  • Patients who do not respond to at least one line of systemic treatment
  • Male and female (with β-HCG negative test)
  • Patients HLA-A*0201
  • Age > 18 years
  • Blood parameters (Hemoglobin ≥ 10g/dl, Leucocytes ≥ 4000/μl,Lymphocytes ≥ 1000/μl, Platelets ≥100.000/μl, creatinin ≤ 2.0mg/dl, bilirubin ≤ 2.0mg/dl, ASAT and ALAT ≤ 2.5 fold the upper normal level)
  • OMS performance score < 3
  • Informed written consent.

Exclusion Criteria:

  • Positive serology for HCV, HBV, HTLV, HIV
  • Protected persons according to French regulations articles L1121-5 to L1121-8 (Public Health Code)
  • Non-pregnant women without effective contraception
  • Any serious acute or chronic illness, for example: active infection, coagulation disorder.
  • Presence of a second cancer in the 5 years preceding inclusion into the study with the exception of in situ cervical carcinoma or a cutaneous carcinoma or other melanoma.
  • Intercurrent disease requiring corticosteroids.
  • Any active autoimmune disease including insulin dependent diabetes mellitus. Vitiligo or autoimmune thyroid disease are not criteria for exclusion.
  • Autoimmune eye disease.
  • Evidence of immunosuppression for any reason
  • Primary ocular melanoma
  • Chemotherapy, immunotherapy or radiotherapy in the 4 weeks preceding inclusion (6 weeks in the case of nitroso-urea and mitomycin C).
  • Treatment with drugs under development within 4 weeks.
  • Cerebral metastases metastasis with the exception of: known metastasis previously treated by surgery or stereotactic radio-surgery, AND Cerebral metastasis, if still present, must be stable for at least 90 days before inclusion and documented with two consecutive MRI or scanner with contrast media, AND, asymptomatic
  • Existence of any surgical or medical condition which, in the judgment of the Investigator, might interfere with this study.
  • Patients who are not willing to comply with the provisions of this protocol.
  Contacts and Locations
Please refer to this study by its identifier: NCT01863108

Contact: Julie Charles, MD, PhD 0033 4 76 76 93 20

University Hospital of Grenoble Recruiting
Grenoble, France, 38000
Sub-Investigator: Julie Charles, MD, PhD         
Sub-Investigator: Isabelle Templier, MD         
Sub-Investigator: Antoine Claeys, MD         
Sponsors and Collaborators
University Hospital, Grenoble
Etablissement Français du Sang
Institut National de la Santé Et de la Recherche Médicale, France
Université Joseph Fourier
Study Director: Joel Plumas, PhD Etablissement Français du Sang
Principal Investigator: Marie-Thérèse Leccia, MD, PhD University Hospital, Grenoble
  More Information

Responsible Party: University Hospital, Grenoble Identifier: NCT01863108     History of Changes
Other Study ID Numbers: DCIC 11 19, 2012-003124-20
Study First Received: May 22, 2013
Last Updated: July 2, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Grenoble:
cancer vaccine
Plasmacytoid dendritic cell line
Advanced Medicinal Therapy Product

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on April 23, 2014